KKKazuyoshi Kawakami

Kazuyoshi Kawakami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kazuyoshi Kawakami has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Ayako Nakahira

    Department of Medical Microbiology, Mycology and Immunology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan

    1 shared publication
  • Chie Kobayashi

    Affiliation Astellas Pharma Inc., Tokyo, Japan

    1 shared publication
  • Emi Kanno

    Department of Translational Science for Nursing, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan, tohoku.ac.jp

    1 shared publication
  • Hideki Araoka

    Department of infectious diseases, Toranomon Hospital , Tokyo

    1 shared publication
  • Hiroaki Hata

    Affiliation Department of Surgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan

    1 shared publication
  • Hiroki Iwaoka

    Department of Medical Microbiology, Mycology and Immunology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan

    1 shared publication

Latest Publications

  • Open Access

    NKT cell–dependent PspA-specific IgA production caused by mucosal administration of a novel nanoparticle pneumococcal vaccine

    by Ayako Nakahira, Hiroki Iwaoka, Ko Sato, Shigenari Ishizuka, Ryuhei Shiroma, Tomomitsu Miyasaka, Emi Kanno, Hiromasa Tanno, Yuki Sato, Yukihiro Akeda, et al.


  • Open Access

    Risk factors for aggravated COVID-19 despite medical care after admission among Japanese patients: A Japanese association for infectious diseases COVID registry study

    by Itaru Nakamura, Yusuke Koizumi, Hideki Araoka, Hiroaki Hata, Takashi Miki, Yusuke Tanaka, Chie Kobayashi, Kazuyoshi Kawakami

    Background: Limited data are available on COVID-19 outcomes in the Japanese population. During the Wuhan strain–dominant period, we investigated factors associated with clinical deterioration of COVID-19 despite inpatient medical care in Japan. Materials and methods: This retrospective, multicenter cohort study used data from the Japanese Association for Infectious Diseases (JAID) COVID registry to identify risk factors for progression to severe disease after hospital admission. The study population included Japanese patients with a confirmed diagnosis of COVID-19 between January 2020 and March 2021. Baseline data included demographics, symptoms at disease onset and admission, and laboratory findings. Univariate and multivariate logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for each explanatory variable associated with disease aggravation. Multiple imputation was used to handle missing data. The predictive performance of two multivariate models—Model I (based on measurable clinical findings) and Model II (based on interview data)—was assessed using the area under the receiver operating characteristic curve (AUC). Results: A total of 2,884 patients were enrolled across 36 institutions in Japan. After excluding 25 ineligible cases and 45 protocol deviations, 2,814 patients were included in the analysis. Multivariate analysis identified several independent risk factors for disease aggravation despite inpatient care, including admission early in the pandemic, older age, impaired consciousness, respiratory distress, elevated BMI, high body temperature, anemia, cholestasis, dehydration, and elevated γ-GTP and LDH levels. The AUCs were 0.8928 for Model I and 0.8862 for Model II, indicating strong discriminatory power. Conclusion: This study identified key risk factors for COVID-19 progression despite inpatient medical care among Japanese patients. These findings underscore the importance of early risk stratification for patients at high risk of deterioration despite treatment and may inform preparedness strategies for future respiratory pandemics.